Pressure BioSciences, Inc. to Present at the 2017 Biotech Showcase

SOUTH EASTON, MA / ACCESSWIRE / January 10, 2017 / Pressure BioSciences, Inc. PBIO ("PB" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at the 9th Annual Biotech Showcase at 5pm PST on Tuesday, January 10, 2017. The Biotech Showcase is being held January 9-11, 2017 at the Hilton San Francisco Union Square, in San Francisco, CA.

About Biotech Showcase

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year. Now in its ninth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers, and industry professionals.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") PBIO develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed nearly 300 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.

For more information, please call Princeton Research, Inc., Mike King, 702.650.3000.

Pressure BioSciences, Inc.
14 Norfolk Avenue, South Easton, MA 02375
TEL 508-230-1828
FAX 508-230-1829
www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO
(T) 508-230-1828

Jeffrey N. Peterson, Chairman
(T) 650 812-8121

SOURCE: Pressure BioSciences, Inc.